FierceBiotech

Decentralized Clinical Trials…

news2025-07-22T11:01:00+00:00July 22nd, 2025|FierceBiotech|

Scancell has linked iSCIB1+ to a…

news2025-07-22T09:21:00+00:00July 22nd, 2025|FierceBiotech|

The FDA has rejected Replimune’s…

news2025-07-22T08:30:00+00:00July 22nd, 2025|FierceBiotech|

Apnimed has scored another phase 3…

news2025-07-21T17:19:00+00:00July 21st, 2025|FierceBiotech|

Choosing the right specialty…

news2025-07-07T14:45:00+00:00July 7th, 2025|FierceBiotech|

The Fierce Biotech Fundraising…

news2024-12-23T12:22:00+00:00December 23rd, 2024|FierceBiotech|

As always, if you know of layoffs…

news2024-12-23T11:52:00+00:00December 23rd, 2024|FierceBiotech|

In a rare rebuke, FDA refuses to fully review Aeglea’s rare disease drug application

news2022-06-02T19:54:11+00:00June 2nd, 2022|FierceBiotech|

UPDATE: Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks. Why not just buy it?

news2022-06-02T15:00:50+00:00June 2nd, 2022|FierceBiotech|

Centessa dumps top program after evidence of tolerability issues stunt market potential

news2022-06-02T14:44:02+00:00June 2nd, 2022|FierceBiotech|

Previous676869Next